Detalles de la búsqueda
1.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37133584
2.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34081848
3.
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Breast Cancer Res Treat
; 203(2): 351-363, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878152
4.
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Cancer
; 127(5): 700-708, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33290610
5.
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
Br J Cancer
; 125(1): 38-47, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33828257
6.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863451
7.
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Breast Cancer Res Treat
; 185(1): 107-116, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32951084
8.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Cancer Res Treat
; 185(3): 697-707, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33159633
9.
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 122(7): 1119, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31949268
10.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28581356
11.
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
Breast Cancer Res Treat
; 179(1): 161-171, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31605311
12.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32274665
13.
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Breast Cancer Res
; 21(1): 153, 2019 12 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31888717
14.
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Cancer
; 125(2): 307-316, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335191
15.
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 120(10): 959-967, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30967649
16.
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Breast Cancer Res Treat
; 177(1): 103-114, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31134488
17.
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Breast Cancer Res Treat
; 2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38592543
18.
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Lancet Oncol
; 19(6): 737-746, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29778737
19.
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Lancet Oncol
; 19(10): 1385-1393, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30196031
20.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(1): 127-138, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158011